Allen Brittainy, Kram Bridgette, Kram Shawn, Schultheis Jennifer, Wolf Steven, Gilstrap Daniel, Shapiro Mark
1 The University of Kansas Hospital, Kansas City, KS, USA.
2 Duke University Hospital, Durham, NC, USA.
Ann Pharmacother. 2018 Feb;52(2):126-132. doi: 10.1177/1060028017729480. Epub 2017 Aug 30.
Vasopressin is commonly used as an adjunct vasopressor in shock. However, response to vasopressin varies among critically ill patients.
To identify patient-specific factors that are associated with vasopressin responsiveness in critically ill adults.
This retrospective, multicenter study included adult patients who were admitted to an intensive care unit (ICU) and received vasopressin for shock. Patients were excluded if they received vasopressin for less than 30 minutes, if vasopressin was initiated prior to ICU arrival, or if an additional vasopressor was initiated within 30 minutes of starting vasopressin. Responsiveness was defined as an increase in mean arterial pressure of ≥10 mm Hg or the ability to taper a concurrent catecholamine vasopressor. Patient-specific factors evaluated in a multivariate analysis included age, gender, ethnicity, body mass index, type of shock, serum pH, Sequential Organ Failure Assessment (SOFA) score, and use of stress-dose steroids. These variables were also evaluated in a subgroup analysis of patients with septic shock.
Of 1619 patients screened, 400 patients were included, with 231 identified as vasopressin responsive and 169 as nonresponsive. Vasopressin used as an adjunct vasopressor, as opposed to first line, during shock was the only variable associated with vasopressin responsiveness (odds ratio [OR] = 1.71; 95% CI = 1.10 to 2.65). Among the subgroup of patients with septic shock, female patients had a higher odds of responding than male patients (OR = 2.10; 95% CI = 1.12 to 3.95).
Vasopressin initiated as an adjunct vasopressor, as opposed to first-line therapy, was associated with response.
血管加压素常用于休克时作为辅助血管升压药。然而,重症患者对血管加压素的反应各不相同。
确定与成年重症患者血管加压素反应性相关的患者特异性因素。
这项回顾性多中心研究纳入了入住重症监护病房(ICU)并因休克接受血管加压素治疗的成年患者。如果患者接受血管加压素治疗少于30分钟、在到达ICU之前就开始使用血管加压素或在开始使用血管加压素后30分钟内开始使用其他血管升压药,则将其排除。反应性定义为平均动脉压升高≥10 mmHg或能够逐渐减少同时使用的儿茶酚胺类血管升压药。多变量分析中评估的患者特异性因素包括年龄、性别、种族、体重指数、休克类型、血清pH值、序贯器官衰竭评估(SOFA)评分以及应激剂量类固醇的使用情况。这些变量也在感染性休克患者的亚组分析中进行了评估。
在筛查的1619例患者中,纳入了400例患者,其中231例被确定为对血管加压素有反应,169例无反应。在休克期间作为辅助血管升压药而非一线用药使用血管加压素是与血管加压素反应性相关的唯一变量(比值比[OR]=1.71;95%置信区间[CI]=1.10至2.65)。在感染性休克患者亚组中,女性患者比男性患者有更高的反应几率(OR=2.10;95%CI=1.12至3.95)。
作为辅助血管升压药而非一线治疗开始使用血管加压素与反应性相关。